Leafix Medical

LeaFix specializes in developing a transcatheter solution for functional mitral valve regurgitation repair, focusing on the augmentation of the anterior leaflet. This innovative system comprises an implant and a delivery mechanism, designed to expand the implant within the leaflet, thereby enlarging the leaflet area and facilitating coaptation. The company targets patients with secondary mitral regurgitation, a condition often linked to left ventricular disease, and aims to provide a minimally invasive alternative to traditional surgical methods. Operating within the transcatheter mitral valve repair market, which was valued at $1.6 billion in 2023 and projected to grow to $2.45 billion by 2030, LeaFix is currently in the animal trial phase, showing promising results. The business model revolves around offering a unique solution that does not require anatomical modification, unlike other methods such as MitralCiip or Pascal. In the event of deployment failure, a transcatheter valve replacement remains feasible without implant retrieval. Co-founded by Dr. Boris Orlov, a seasoned cardiac surgeon, and Boaz Harari, an engineer with two decades of experience, LeaFix leverages their expertise to advance minimally invasive therapies for structural heart disease. Keywords: transcatheter, mitral valve, regurgitation, anterior leaflet, minimally invasive, cardiac surgery, implant, delivery system, animal trial, heart disease.